Indeed, EZH2 also physically associates with MYC or MYCN in other cellular contexts, including neuroblastoma and prostate cancer cells, to drive cancer development, making EZH2 degradation an attractive strategy for cancer treatment (147–150). Here, EZH2 is linked to prostate carcinoma.